DC
IMRX icon

Diametric Capital’s Immuneering IMRX Stock Holding History

Diametric Capital’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$922K Sell
174,897
-71,960
-29% -$369K 0.24% 110
2025
Q4 		$1.62M Sell
246,857
-5,336
-2% -$34.3K 0.44% 49
2025
Q3 		$1.77M Buy
+252,193
New +$1.31M 0.65% 30

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Diametric Capital's IMRX Position: Q1 2026 in Review

Diametric Capital reduced its Immuneering (IMRX) stake by 29% in Q1 2026, selling an estimated $369K and leaving 174,897 shares worth $922K. The position accounts for 0.24% of the portfolio, ranked #110.

Diametric Capital first reported a position in IMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.77M in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Diametric Capital held 174,897 shares of Immuneering worth $922K as of Q1 2026.
  • Diametric Capital sold 71,960 Immuneering shares in Q1 2026, an estimated $369K.
  • Immuneering made up 0.24% of Diametric Capital's portfolio in Q1 2026, its #110 holding.
  • Diametric Capital first reported a position in Immuneering in Q3 2025 and has held it in 3 quarters since.
  • Diametric Capital's Immuneering position peaked at $1.77M in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Diametric Capital's 13F filing for Q1 2026, filed 15 May 2026.